lasmiditan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antimigraine (5-HT1 receptor agonists)	5351	439239-90-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lasmiditan lasmiditan succinate COL-144 LY-573144 reyvow rayvow	Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist for oral administration, bindinding with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown. Molecular weight: 377.37 Formula: C19H18F3N3O2 CLOGP: 1.98 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 62.30 ALOGS: -4.33 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lasmiditan
lasmiditan succinate
COL-144
LY-573144
reyvow
rayvow

Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist for oral administration, bindinding with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown.

Molecular weight: 377.37
Formula: C19H18F3N3O2
CLOGP: 1.98
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 62.30
ALOGS: -4.33
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
Aug. 17, 2022	EMA	Eli Lilly Nederland B.V.
Jan. 20, 2022	PMDA	ELI LILLY JAPAN K.K.
Nov. 10, 2019	FDA	ELI LILLY AND CO

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dizziness	234.54	101.88	101	507	429824	63058590
Feeling abnormal	157.47	101.88	57	551	148335	63340079
Sedation	153.60	101.88	41	567	38768	63449646
Somnolence	102.09	101.88	44	564	178641	63309773

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dizziness	146.91	84.25	55	190	526386	79217757

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N02CC08	NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Migraine	indication	37796009	DOID:6364

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.03	acidic
pKa2	9.43	Basic
pKa3	0.49	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	8748459	March 27, 2023	ACUTE TREATMENT OF MIGRAINE
EQ 100MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	7423050	Feb. 17, 2028	ACUTE TREATMENT OF MIGRAINE
EQ 100MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	11053214	Dec. 5, 2037	ACUTE TREATMENT OF MIGRAINE
EQ 200MG BASE	REYVOW	ELI LILLY AND CO	N211280	Dec. 18, 2020	DISCN	TABLET	ORAL	8748459	March 27, 2023	ACUTE TREATMENT OF MIGRAINE
EQ 200MG BASE	REYVOW	ELI LILLY AND CO	N211280	Dec. 18, 2020	DISCN	TABLET	ORAL	7423050	Feb. 17, 2028	ACUTE TREATMENT OF MIGRAINE
EQ 200MG BASE	REYVOW	ELI LILLY AND CO	N211280	Dec. 18, 2020	DISCN	TABLET	ORAL	11053214	Dec. 5, 2037	ACUTE TREATMENT OF MIGRAINE
EQ 50MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	8748459	March 27, 2023	ACUTE TREATMENT OF MIGRAINE
EQ 50MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	7423050	Feb. 17, 2028	ACUTE TREATMENT OF MIGRAINE
EQ 50MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	11053214	Dec. 5, 2037	ACUTE TREATMENT OF MIGRAINE

Showing 1 to 9 of 9 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	Jan. 31, 2025	NEW CHEMICAL ENTITY
EQ 200MG BASE	REYVOW	ELI LILLY AND CO	N211280	Dec. 18, 2020	DISCN	TABLET	ORAL	Jan. 31, 2025	NEW CHEMICAL ENTITY
EQ 50MG BASE	REYVOW	ELI LILLY AND CO	N211280	Jan. 31, 2020	RX	TABLET	ORAL	Jan. 31, 2025	NEW CHEMICAL ENTITY

Showing 1 to 3 of 3 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
5-hydroxytryptamine receptor 1F	GPCR	P30939	5HT1F_HUMAN	AGONIST	Ki	8.65		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
018168	NDDF
018169	NDDF
05X	PDB_CHEM_ID
11610526	PUBCHEM_CID
2256930	RXNORM
325205	MMSL
3928	IUPHAR_LIGAND_ID
4039151	VANDF
439239-92-6	SECONDARY_CAS_RN
760I9WM792	UNII

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-0265	TABLET	50 mg	ORAL	Export only	1 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-0265	TABLET	50 mg	ORAL	Export only	1 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-0632	TABLET	100 mg	ORAL	Export only	1 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-0632	TABLET	100 mg	ORAL	Export only	1 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4312	TABLET	50 mg	ORAL	NDA	32 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4312	TABLET	50 mg	ORAL	NDA	32 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4312	TABLET	50 mg	ORAL	NDA	32 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4491	TABLET	100 mg	ORAL	NDA	32 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4491	TABLET	100 mg	ORAL	NDA	32 sections
Reyvow	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4491	TABLET	100 mg	ORAL	NDA	32 sections

Showing 1 to 10 of 10 entries

Previous1Next